Just sent the following out with stocktwits.com to twitter.com...

$LDSR Short Term 40% Buy; Medium Term 25% Buy; Long Term 100% Buy http://quote.barchart.com/texpert.asp?sym=LDSR&code=BSTK

$HTDS Short Term 20% Buy; Medium Term 25% Buy; Long Term 100% Buy; Overall 48% Buy http://quote.barchart.com/texpert.asp?sym=HTDS&code=BSTK

$CTIC Short Term HOLD; Medium Term 75% Buy; Long Term 67% Buy; Overall 48% Buy http://quote.barchart.com/texpert.asp?sym=CTIC&code=BSTK

$GETA Short Term 60% Buy; Medium Term 75% Buy; Long Term 67% Buy; Overall 72% Buy http://quote.barchart.com/texpert.asp?sym=GETA&code=BSTK

About CTIC

Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer.

About GETA

Genta Incorporated (Genta), is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases. Genta’s research portfolio consists of two major programs: Deoxyribonucleic Acid (DNA)/Ribonucleic Acid (RNA) Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys and small interfering or micro RNAs. Genta’s drug from this program is an investigational antisense compound known as Genasense (oblimersen sodium injection). The Small Molecules program includes drugs, such as Ganite and investigational compounds tesetaxel and G4544.

Note: At the time this article was written, the author held shares in HTDS, LDSR, CTIC and GETA.

Tags: Ldsr Htds Ctic Geta Barcharts Opinion

Bookmark: